AstraZeneca Pharma India (NSE:ASTRAZEN) Growth Rank: 8 (As of Aug. 09, 2026) — 167% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
92 GF Score
Price ₹8,191.00
GF Value ₹11,103.59
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Growth Rank?

AstraZeneca Pharma India NSE:ASTRAZEN +1.43% 92 Growth Rank is 8 as of Aug. 09, 2026, which is 167% above its 10-year median of 3.00. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 92/100 and a GF Value™ of ₹11,103.59 (Modestly Undervalued). The stock has 5 warning signs investors should review.

AstraZeneca Pharma India has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

AstraZeneca Pharma India Growth Rank Related Terms

NSE:ASTRAZEN vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pharma India Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Growth Rank distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Growth Rank falls into.


NSE:ASTRAZEN
92GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Growth Rank of 8 as of Aug. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on AstraZeneca Pharma India and its competitors. This is 167% above median its historical median of 3.00. Over the past decade, AstraZeneca Pharma India's Growth Rank has ranged from 1.00 to 8.00.
Is AstraZeneca Pharma India's Growth Rank too high?
AstraZeneca Pharma India's current Growth Rank of 8 is 167% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Growth Rank compare to ZTS?
AstraZeneca Pharma India's Growth Rank of 8 can be compared against companies in the Drug Manufacturers industry. Historically, AstraZeneca Pharma India's own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Growth Rank is 8, which is 167% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹11,103.59, compared to a current price of ₹8,191.00 — trading 26.2% below its estimated fair value. The current Growth Rank is 8, which is 167% above median its 10-year median of 3.00. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Growth Rank is 8 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,191.00 is trading 26.2% below its estimated GF Value™ of ₹11,103.59. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • Growth Rank: 8 (167% above median its 10-year median of 3.00)
  • GF Value™: ₹11,103.59 vs. price of ₹8,191.00 (26.2% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score

Get the complete analysis for NSE:ASTRAZEN

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,191.00
Price
₹11,103.59
GF Value